KR101570383B1 - 조성물 - Google Patents

조성물 Download PDF

Info

Publication number
KR101570383B1
KR101570383B1 KR1020107005853A KR20107005853A KR101570383B1 KR 101570383 B1 KR101570383 B1 KR 101570383B1 KR 1020107005853 A KR1020107005853 A KR 1020107005853A KR 20107005853 A KR20107005853 A KR 20107005853A KR 101570383 B1 KR101570383 B1 KR 101570383B1
Authority
KR
South Korea
Prior art keywords
mbp
hla
peptide
seq
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107005853A
Other languages
English (en)
Korean (ko)
Other versions
KR20100036391A (ko
Inventor
데이비드 레이트
헤더 스트리터
Original Assignee
아피토프 테크놀러지 (브리스톨) 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed by 아피토프 테크놀러지 (브리스톨) 리미티드 filed Critical 아피토프 테크놀러지 (브리스톨) 리미티드
Publication of KR20100036391A publication Critical patent/KR20100036391A/ko
Application granted granted Critical
Publication of KR101570383B1 publication Critical patent/KR101570383B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
KR1020107005853A 2007-10-31 2008-10-30 조성물 Active KR101570383B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0721430.7 2007-10-31
GB0800962.3 2008-01-18
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition

Publications (2)

Publication Number Publication Date
KR20100036391A KR20100036391A (ko) 2010-04-07
KR101570383B1 true KR101570383B1 (ko) 2015-11-19

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107005853A Active KR101570383B1 (ko) 2007-10-31 2008-10-30 조성물

Country Status (23)

Country Link
US (3) US8623827B2 (https=)
EP (1) EP2211892B1 (https=)
JP (1) JP5361895B2 (https=)
KR (1) KR101570383B1 (https=)
CN (1) CN101848725B (https=)
AT (1) ATE518546T1 (https=)
AU (1) AU2008320657B2 (https=)
BR (1) BRPI0818302B1 (https=)
CA (1) CA2703170C (https=)
CY (1) CY1112620T1 (https=)
DK (1) DK2211892T3 (https=)
EA (1) EA017999B1 (https=)
EC (1) ECSP10010211A (https=)
HR (1) HRP20110724T1 (https=)
IL (1) IL204662A (https=)
MX (1) MX2010004698A (https=)
MY (1) MY158800A (https=)
NZ (1) NZ583924A (https=)
PL (1) PL2211892T3 (https=)
PT (1) PT2211892E (https=)
SI (1) SI2211892T1 (https=)
WO (1) WO2009056833A2 (https=)
ZA (1) ZA201001748B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1731912T1 (sl) 2000-08-21 2014-05-30 Apitope Technology (Bristol) Limited Postopek izbire peptida
AU2008320657B2 (en) 2007-10-31 2013-09-05 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Composition
DK2488196T3 (en) * 2009-10-12 2016-03-14 Lifebio Lab Llc A composition for treating multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
WO2018127828A1 (en) * 2017-01-04 2018-07-12 Apitope International Nv Therapeutic method using tolerogenic peptides
JP7419229B2 (ja) * 2017-08-14 2024-01-22 百明信康生物技術（浙江）有限公司 方法
BR112023021222A2 (pt) 2021-04-16 2024-01-16 Cour Pharmaceuticals Dev Company Inc Método de rastreamento de manutenção de tolerância imunológica

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016410A2 (en) * 2000-08-21 2002-02-28 Apitope Technology (Bristol) Limited Peptide selection method
WO2003064464A1 (en) * 2002-02-01 2003-08-07 Apitope Technology (Bristol) Limited Tolerogenic peptides from myelin basic protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US20040096456A1 (en) 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
AU2008320657B2 (en) 2007-10-31 2013-09-05 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016410A2 (en) * 2000-08-21 2002-02-28 Apitope Technology (Bristol) Limited Peptide selection method
WO2003064464A1 (en) * 2002-02-01 2003-08-07 Apitope Technology (Bristol) Limited Tolerogenic peptides from myelin basic protein

Also Published As

Publication number Publication date
AU2008320657B2 (en) 2013-09-05
ATE518546T1 (de) 2011-08-15
JP5361895B2 (ja) 2013-12-04
NZ583924A (en) 2012-06-29
CN101848725A (zh) 2010-09-29
US9775880B2 (en) 2017-10-03
HK1142803A1 (en) 2010-12-17
ECSP10010211A (es) 2010-08-31
US20100286054A1 (en) 2010-11-11
PL2211892T3 (pl) 2012-01-31
EP2211892A2 (en) 2010-08-04
SI2211892T1 (sl) 2011-12-30
CN101848725B (zh) 2013-05-22
EA017999B1 (ru) 2013-04-30
IL204662A0 (en) 2010-11-30
AU2008320657A1 (en) 2009-05-07
WO2009056833A2 (en) 2009-05-07
EA201070541A1 (ru) 2010-12-30
MY158800A (en) 2016-11-15
US8623827B2 (en) 2014-01-07
CA2703170A1 (en) 2009-05-07
KR20100036391A (ko) 2010-04-07
US20140161832A1 (en) 2014-06-12
HRP20110724T1 (hr) 2011-12-31
WO2009056833A3 (en) 2009-11-26
CA2703170C (en) 2016-10-11
IL204662A (en) 2013-07-31
MX2010004698A (es) 2010-05-13
BRPI0818302A2 (https=) 2018-08-21
CY1112620T1 (el) 2016-02-10
DK2211892T3 (da) 2011-10-31
JP2011500776A (ja) 2011-01-06
US9381234B2 (en) 2016-07-05
US20160263188A1 (en) 2016-09-15
EP2211892B1 (en) 2011-08-03
BRPI0818302B1 (pt) 2022-04-12
PT2211892E (pt) 2011-10-18
ZA201001748B (en) 2011-06-29

Similar Documents

Publication Publication Date Title
KR101570383B1 (ko) 조성물
US8343500B2 (en) Peptide composition
AU672313B2 (en) Composition for preventing or treating a T cell mediated pathology
RU2676149C2 (ru) Пептиды
EP0522091B1 (en) Use of a mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
JP3434510B2 (ja) ミエリン塩基性タンパク質のペプチドフラグメントを用いたｔ‐細胞増殖の抑制
CA2203629A1 (en) Compositions and treatment for multiple sclerosis
CN105120894A (zh) 新颖的免疫治疗分子和其用途
KR102169902B1 (ko) 펩타이드
AU2018316662A1 (en) Method
ES2370957T3 (es) Composiciones que comprenden péptidos de la proteína básica de la mielina y sus utilizaciones médicas.
HK1142803B (en) Compositions comprising myelin basic protein peptides and medical uses thereof
CN115298195B (zh) 一种包含s-阻遏蛋白肽的组合物
WO2003000718A2 (en) Polypeptides comprising t cell epitopes from alpha-fodrin and the uses thereof in treatment of sjögren's syndrome

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100317

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130826

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150223

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20150827

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20151113

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20151113

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20181018

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20181018

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20191114

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20191114

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20210507

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20210507

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20211115

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20211115

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20221205

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20221205

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20231108

Start annual number: 9

End annual number: 9